Your browser is no longer supported. Please, upgrade your browser.
Settings
BTX BioTime, Inc. daily Stock Chart
BTX [NYSE]
BioTime, Inc.
Index- P/E- EPS (ttm)-1.06 Insider Own0.80% Shs Outstand134.73M Perf Week3.49%
Market Cap319.31M Forward P/E- EPS next Y-0.28 Insider Trans0.00% Shs Float118.67M Perf Month0.00%
Income-132.80M PEG- EPS next Q-0.08 Inst Own44.80% Short Float7.94% Perf Quarter-10.57%
Sales3.80M P/S84.03 EPS this Y-151.70% Inst Trans-2.78% Short Ratio26.24 Perf Half Y1.72%
Book/sh0.79 P/B3.00 EPS next Y60.00% ROA-76.00% Target Price6.63 Perf Year-21.78%
Cash/sh0.23 P/C10.17 EPS next 5Y- ROE-83.40% 52W Range2.08 - 3.21 Perf YTD10.23%
Dividend- P/FCF- EPS past 5Y16.70% ROI18.30% 52W High-26.17% Beta1.89
Dividend %- Quick Ratio6.20 Sales past 5Y-2.50% Gross Margin94.20% 52W Low13.89% ATR0.10
Employees92 Current Ratio6.20 Sales Q/Q75.00% Oper. Margin- RSI (14)55.94 Volatility4.06% 4.48%
OptionableYes Debt/Eq0.01 EPS Q/Q-209.10% Profit Margin- Rel Volume0.84 Prev Close2.31
ShortableYes LT Debt/Eq0.01 EarningsMay 10 AMC Payout- Avg Volume359.33K Price2.37
Recom1.80 SMA203.43% SMA503.20% SMA200-6.64% Volume301,718 Change2.60%
Feb-02-18Initiated Lake Street Buy $8
Mar-31-17Initiated Raymond James Outperform $6
Sep-23-16Initiated Ladenburg Thalmann Buy
Feb-19-16Initiated Chardan Capital Markets Buy $5
Dec-22-15Initiated Oppenheimer Outperform $10
Dec-19-11Upgrade WBB Securities Buy → Strong Buy $8
Nov-16-11Upgrade WBB Securities Speculative Buy → Buy $6 → $8
Aug-11-11Initiated WBB Securities Speculative Buy $6
Jan-06-11Initiated BioLogic Equity Research Sell $2
Jun-19-18 07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-14-18 11:37AM  June Fundamental Stock Pick: Forbuild SA (WSE:BTX) Simply Wall St.
08:15AM  Detailed Research: Economic Perspectives on Verizon Communications, PayPal, Menlo Therapeutics, iClick Interactive Asia Group, BioTime, and Adobe What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-11-18 07:00AM  AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence Business Wire
Jun-08-18 07:00AM  BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares Business Wire
Jun-05-18 07:00AM  AgeX Therapeutics Appoints John F. Mauldin to Board of Directors Business Wire +5.06%
May-30-18 07:00AM  BioTime to Present at the 8th Annual LD Micro Invitational Business Wire
May-29-18 07:00AM  BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD Business Wire
May-24-18 07:00AM  BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites Business Wire
May-22-18 04:15AM  How Does Forbuild SAs (WSE:BTX) Earnings Growth Stack Up Against Industry Performance? Simply Wall St.
May-17-18 07:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London Business Wire
May-16-18 09:53PM  Edited Transcript of BTX earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 05:23PM  BioTime: 1Q Earnings Snapshot Associated Press
04:05PM  BioTime Reports First Quarter Results and Recent Corporate Accomplishments Business Wire
11:47AM  BioTime Inc (NYSEMKT:BTX): Earnings Expected To Remain Subdued Simply Wall St.
May-02-18 07:00AM  AgeX Announces NIH Grant Award Business Wire
May-01-18 11:02AM  With An ROE Of 9.05%, Has Forbuild SAs (WSE:BTX) Management Done Well? Simply Wall St.
08:00AM  BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO Business Wire
Apr-26-18 07:00AM  BioTime to Announce First Quarter 2018 Results on May 10, 2018 Business Wire
Apr-16-18 07:00AM  Data from BioTimes OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018 Business Wire
Apr-10-18 07:41AM  BioTime (BTX): Moving Average Crossover Alert Zacks +5.06%
Apr-09-18 08:00AM  Data from BioTimes OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit Business Wire
Mar-27-18 07:00AM  BioTime Announces Cash Sale of Ascendance Biotechnology Business Wire
Mar-21-18 07:40AM  Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin ACCESSWIRE
Mar-16-18 01:20PM  Edited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents +9.84%
Mar-15-18 05:35PM  BioTime reports 4Q loss Associated Press -8.30%
04:05PM  BioTime Reports Fourth Quarter and Fiscal 2017 Results Business Wire
12:00PM  BioTime, Inc. to Host Earnings Call ACCESSWIRE
10:44AM  BioTime Q4 Earnings Outlook Benzinga
Mar-14-18 08:38AM  BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session Zacks
08:10AM  Research Report Identifies Supernus Pharmaceuticals, Celestica, Global Blood Therapeutics, BioTime, CyberArk Software, and Tivity Health, Inc. with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-13-18 08:00AM  BioTime Submits CE Mark Application for European Approval of Renevia® Business Wire +5.99%
Mar-07-18 08:00AM  BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial Business Wire
Mar-05-18 08:00AM  BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018 Business Wire
Mar-01-18 08:00AM  AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018 Business Wire
Feb-28-18 08:00AM  BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference Business Wire
Feb-26-18 07:00AM  BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs Business Wire
Feb-22-18 07:00AM  BioTime Appoints Cavan Redmond to Its Board of Directors Business Wire
Feb-15-18 07:00AM  Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018 Business Wire
Feb-07-18 07:00AM  BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018 Business Wire
Jan-29-18 07:00AM  Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference Business Wire +7.27%
Jan-23-18 07:00AM  BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018 Business Wire
Jan-22-18 07:00AM  BioTime Announces Clinical and Corporate Milestone Targets for 2018 Business Wire
Jan-18-18 07:00AM  AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on Stem Cell Innovations That Will Change the World Business Wire
Jan-17-18 07:00AM  BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate Business Wire
Jan-05-18 04:30PM  AgeX Therapeutics to Present at Biotech Showcase Annual Conference Business Wire
Jan-02-18 07:00AM  AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer Business Wire +6.51%
Dec-29-17 11:38AM  ETFs with exposure to BioTime, Inc. : December 29, 2017 Capital Cube
Dec-20-17 07:49AM  Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys Zacks
07:00AM  BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 Business Wire
Dec-19-17 06:23AM  Try Rising P/E Investing With 5 Top-Ranked Stocks Zacks
Dec-18-17 02:59PM  ETFs with exposure to BioTime, Inc. : December 18, 2017 Capital Cube
Dec-07-17 01:06PM  ETFs with exposure to BioTime, Inc. : December 7, 2017 Capital Cube
Dec-05-17 09:35AM  Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys Zacks
08:53AM  BioTime, Inc. :BTX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017 Capital Cube
Dec-04-17 08:00AM  Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference Business Wire
07:00AM  AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas Annual Conference on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, NC Business Wire
Dec-01-17 09:33AM  Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime Zacks
Nov-30-17 08:20AM  5 Affordable Breakout Stocks Offering Excellent Returns Zacks
07:00AM  Data from BioTimes Renevia® Program to Be Presented at IFATS Conference Business Wire
Nov-29-17 02:03AM  BioTime, Inc. is trading above its 50 day moving average : BTX-US : November 29, 2017 Capital Cube
Nov-28-17 01:37PM  BioTime, Inc. Value Analysis (NYSE AMERICAN:BTX) : November 28, 2017 Capital Cube
Nov-27-17 07:30AM  BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : November 27, 2017 Capital Cube
Nov-15-17 11:13AM  BioTime, Inc.: Trading close to its 50 day moving average. Good buy? Capital Cube
08:00AM  BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO Business Wire
Nov-14-17 12:41AM  Edited Transcript of BTX earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-17 07:00AM  BioTime to Participate in Upcoming Conferences Business Wire -5.08%
Nov-10-17 11:58AM  ETFs with exposure to BioTime, Inc. : November 10, 2017 Capital Cube +13.78%
Nov-09-17 04:59PM  BioTime beats 3Q profit forecasts Associated Press
04:05PM  BioTime Reports Third Quarter Results and Recent Corporate Accomplishments Business Wire
02:40PM  Edited Transcript of BTX earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
12:25PM  Is It Time To Buy BioTime Inc (BTX)? Simply Wall St.
Nov-08-17 07:00AM  AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London Business Wire
Nov-02-17 12:00AM  BioTime to Participate in the Jefferies 2017 London Healthcare Conference Business Wire
Oct-26-17 10:22AM  ETFs with exposure to BioTime, Inc. : October 26, 2017 Capital Cube
07:00AM  AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economists Conference The Business of Longevity: Health Innovation for an Ageing World October 27 in Hong Kong Business Wire
Oct-24-17 07:00AM  BioTime to Announce Third Quarter 2017 Results on November 9, 2017 Business Wire
Oct-18-17 03:03AM  BioTime, Inc. is trading below its 50 day moving average : BTX-US : October 18, 2017 Capital Cube
Oct-17-17 04:05PM  BioTime, Inc. Announces Closing of Public Offering and Underwriters Full Exercise of Over-Allotment Option Business Wire
Oct-13-17 09:15AM  BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock Business Wire
07:10AM  Corporate News Blog - BioTime to Sublicense Hystem(R) to Processa Pharma for Developing Drug Delivery Platforms ACCESSWIRE
Oct-12-17 04:05PM  BioTime, Inc. Announces Proposed Public Offering of Common Stock Business Wire
Oct-11-17 08:00AM  BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit Business Wire
07:00AM  BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery Business Wire
Oct-04-17 10:37AM  ETFs with exposure to BioTime, Inc. : October 4, 2017 Capital Cube
Oct-03-17 07:00AM  BioTime to Present at the Cell and Gene Meeting on the Mesa Business Wire
Sep-26-17 07:00AM  BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial Business Wire
Sep-25-17 07:00AM  BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders Business Wire
Sep-22-17 11:05AM  ETFs with exposure to BioTime, Inc. : September 22, 2017 Capital Cube
09:00AM  BioTime - A Multi-Faceted Regenerative Medicine Company ACCESSWIRE
Sep-21-17 12:10PM  BioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017 Capital Cube
10:16AM  BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : September 21, 2017 Capital Cube
07:00AM  BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum Business Wire
07:00AM  AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum Business Wire
03:09AM  BioTime, Inc. is trading above its 50 day moving average : BTX-US : September 21, 2017 Capital Cube
Sep-20-17 07:00AM  BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference Business Wire
07:00AM  BioTime to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-18-17 07:00AM  BioTime Awarded Grant from the NIH Business Wire
Sep-14-17 05:43PM  Two Key BioTime Patents Providing Protection to OpRegen® Remain Upheld Business Wire
Sep-11-17 09:55PM  ETFs with exposure to BioTime, Inc. : September 12, 2017 Capital Cube
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEST MICHAEL DCo-Chief Executive OfficerApr 10Option Exercise0.001,5630886,278Apr 12 09:00 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerApr 10Option Exercise0.004,688099,940Apr 12 08:39 PM
WEST MICHAEL DCo-Chief Executive OfficerJan 10Option Exercise0.001,5620885,401Jan 12 08:30 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerJan 10Option Exercise0.004,687097,309Jan 12 09:17 PM
BROADWOOD PARTNERS, L.P.DirectorOct 13Buy2.602,692,3076,999,99829,971,561Oct 17 05:58 PM
WEST MICHAEL DCo-Chief Executive OfficerOct 10Option Exercise0.001,5630884,427Oct 12 07:35 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerOct 10Option Exercise0.004,688094,384Oct 12 09:35 PM
SKIBSTED RUSSELLChief Financial OfficerAug 23Buy2.642,0005,2852,000Aug 25 04:33 PM
BROADWOOD PARTNERS, L.P.DirectorAug 22Buy2.6010,00025,95527,279,254Aug 24 06:58 PM
WEST MICHAEL DCo-Chief Executive OfficerAug 22Buy2.602,0005,198882,864Aug 23 07:23 PM
ANDREWS DEBORAH JDirectorAug 21Buy2.502,3965,9908,396Aug 23 06:31 PM
Patton Stephana EileneGeneral CounselAug 21Buy2.587,50019,3767,500Aug 22 08:43 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerAug 21Buy2.507,50018,75089,696Aug 22 08:22 PM
BROADWOOD PARTNERS, L.P.DirectorJul 31Buy2.80150,000420,00027,269,254Aug 02 06:37 PM
KINGSLEY ALFRED DSee RemarksJul 31Sale2.80150,000420,0005,781,555Aug 02 06:27 PM
WEST MICHAEL DCo-Chief Executive OfficerJul 10Option Exercise0.001,5620881,451Jul 12 07:21 PM
MOHANTY ADITYA P.Co-Chief Executive OfficerJul 10Option Exercise0.004,687083,958Jul 12 07:26 PM